Exosomal Thioredoxin-1 from Hypoxic Human Umbilical Cord Mesenchymal Stem Cells Inhibits Ferroptosis in Doxorubicin-induced Cardiotoxicity Via MTORC1 Signaling
Overview
Biology
General Medicine
Authors
Affiliations
Doxorubicin (DOX), a clinical chemotherapeutic drug, is often annoyed by its cardiotoxicity which involves ferroptosis in its pathological progress. Human umbilical cord mesenchymal stem cells (HucMSCs)-derived exosomes (HucMSCs-Exo) are proven effective in treating cardiovascular diseases. This study aimed to compare the therapeutic effects between normoxic HucMSCs-Exo (Exo) and hypoxic HucMSCs-Exo (Hypo-Exo) on DOX-induced ferroptosis and explore the underlying mechanisms. An acute cardiotoxicity model was successfully constructed by administrating two doses intraperitoneal injections of DOX (25 mg/kg in total). Exo and Hypo-Exo were extracted by ultracentrifugation and characterized. Compared with Exo, Hypo-Exo and Ferrostatin-1 (Fer-1) exerted superior effects on inhibiting DOX-induced ferroptosis, as evidenced by decreasing malondialdehyde (MDA), iron content and increasing glutathione (GSH) level as well as ferroptosis-related genes expression including prostaglandin-endoperoxide synthase 2 (Ptgs2) mRNA level and glutathione peroxidase 4 (GPX4) protein level. Based on quantitative proteomics analysis, we found that thioredoxin1 (Trx1) was remarkably upregulated in Hypo-Exo and exhibited anti-ferroptosis activity via activating the mechanistic target of rapamycin complex 1 (mTORC1) in neonatal rat cardiomyocytes (NRCMs). Trx1 knockdown and rapamycin (an mTORC1 inhibitor) partially abolished the protective effects of Hypo-Exo. Furthermore, our data indicated that solute carrier family 7 member 11 (SLC7A11) was critical for GPX4 protein synthesis. In conclusion, Hypo-Exo exhibited a better suppression of ferroptosis in DOX-induced cardiotoxicity. Trx1-mediated mTORC1 activation is critical for the Hypo-Exo anti-ferroptosis process, which involves increased GPX4 protein synthesis and decreased iron overload. This study indicated that Hypo-Exo may present a potential strategy against ferroptosis in DOX-induced cardiotoxicity.
Zhang A, Li Q, Chen Z Int J Mol Sci. 2025; 26(1.
PMID: 39796081 PMC: 11719504. DOI: 10.3390/ijms26010225.
The Potential of Mesenchymal Stem Cell-Derived Exosomes in Cardiac Repair.
Kundu D, Shin S, Chilian W, Dong F Int J Mol Sci. 2025; 25(24.
PMID: 39769256 PMC: 11727646. DOI: 10.3390/ijms252413494.
Wu T, Lu Y, Yu Y, Hua Y, Ge G, Zhao W Cell Mol Life Sci. 2024; 81(1):432.
PMID: 39395058 PMC: 11470913. DOI: 10.1007/s00018-024-05464-0.
Advances in application of hypoxia-preconditioned mesenchymal stem cell-derived exosomes.
Zhuo H, Chen Y, Zhao G Front Cell Dev Biol. 2024; 12:1446050.
PMID: 39239560 PMC: 11375678. DOI: 10.3389/fcell.2024.1446050.
Mesenchymal stem cells and ferroptosis: Clinical opportunities and challenges.
Cui M, Chen F, Shao L, Wei C, Zhang W, Sun W Heliyon. 2024; 10(3):e25251.
PMID: 38356500 PMC: 10864896. DOI: 10.1016/j.heliyon.2024.e25251.